CTOs on the Move

POINTONE Systems

www.pointone.ws

 
POINTONE Systems is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.pointone.ws
  • 10437 W Innovation Dr
    Milwaukee, WI USA 53226
  • Phone: 414.771.1802

Executives

Name Title Contact Details

Similar Companies

ATAI Life Sciences

Bridging the gap between what the #mentalhealth system can provide and what people need. Interested in #psychedelics, #drugdevelopment, and #AI. CEO @FloBrand.

Sekisui Diagnostics

Sekisui Diagnostics, a global provider of innovative medical diagnostics to physicians and laboratories, has been committed to improving the lives of patients for over 30 years.

Dance Biopharm

Dance Biopharm is a private company focused on developing novel inhaled formulations of medicines to treat diabetes and other serious chronic diseases.

GluStitch

GluStitch, Inc. is a Delta, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Calithera

Calithera is discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera Biosciences is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Tumor metabolism and tumor immunology have emerged as promising new fields for cancer drug discovery, and recent clinical successes with therapeutic agents in each field have demonstrated the potential to create fundamentally new therapies for cancer patients. Our lead product candidate in tumor metabolism, CB-839, is an internally discovered, first-in-class inhibitor of glutaminase, a critical enzyme in tumor metabolism. We are currently evaluating CB-839 in three Phase 1 clinical trials in solid and hematological tumors. In tumor immunology, our lead preclinical program is directed at developing inhibitors of the enzyme arginase and may provide a first-in-class therapeutic agent for this novel target. Our ongoing research efforts are focused on discovering additional product candidates against novel tumor metabolism and immunology targets.